Physician profile
Robert Schmidt
NPI 1811949381
$4,895.63
in general payments reported to CMS, 2019-2025
32 companies · $20.76 in 2025
The $20.76 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $1,580 · 2021: $1,330 · 2022: $652 · 2023: $34.35 · 2024: $17.06 · 2025: $20.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $750.62 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $695.24 | 2019-2022 | |
| Abbvie INC. | $590.75 | 2021-2022 | |
| Novo Nordisk INC | $476.74 | 2019-2022 | |
| Allergan, INC. | $439.98 | 2019-2021 | |
| Glaxosmithkline, LLC. | $293.64 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $254.78 | 2019-2022 | |
| Pfizer INC. | $185.62 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.98 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $139.17 | 2019-2022 | |
| Lilly USA, LLC | $88.92 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $81.84 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $79.31 | 2019-2022 | |
| Astellas Pharma US INC | $67.43 | 2019-2021 | |
| Philips North America LLC | $57.25 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $55.63 | 2019 | |
| Indivior INC. | $54.99 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $54.08 | 2019 | |
| Eisai INC. | $51.37 | 2021 | |
| Mallinckrodt Hospital Products INC. | $49.76 | 2020 | |
| Alkermes, INC. | $44.72 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $42.68 | 2020-2021 | |
| Qiagen, LLC | $34.35 | 2023 | |
| Galderma Laboratories, L.P. | $20.76 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.18 | 2022 | |
| Axsome Therapeutics, INC. | $17.06 | 2024 | Sunosi |
| Redhill Biopharma INC. | $15.03 | 2020 | |
| Mdd US Operations, LLC | $14.69 | 2019 | |
| Medline Industries Lp | $14.29 | 2019 | |
| Biodelivery Sciences International, INC. | $12.23 | 2019 | |
| Lundbeck LLC | $11.66 | 2021 | |
| Orexo US, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.